Added to YB: 2026-08-04
Pitch date: 2026-07-31
SHILPAMED.NS [neutral]
Shilpa Medicare Limited
+1.56%
current return
Author Info
No bio for this author
Company Info
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally.
Market Cap
INR 119.6B
Pitch Price
INR 613.70
Price Target
N/A
Dividend
0.10%
EV/EBITDA
27.83
P/E
49.16
EV/Sales
8.17
Sector
Pharmaceuticals
Category
growth
Shilpa Medicare Quietly Building What Most Investors Think Doesn't Exist
SHILPAMED.NS (overview): Indian pharma transforming from oncology API maker into diversified specialty platform (formulations, biologics, CDMO, peptides, GLP-1, ADCs). Q4FY26 rev ₹437Cr (+32% YoY), EBITDA +51%, OPM 27%, adj PAT +147% (some one-offs). Net debt/EBITDA 6.7x→1.4x. Trades 27x EV/EBITDA; turnaround priced in, FY27 commercialization is proof year. Key risks: execution/timing, regulatory, GLP-1 competition. Promoter stake down 50%→40%; FII/DII rising.
Read full article (33 min)